Self-inactivating retroviral vectors with improved RNA processing
- 16 September 2004
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 11 (21) , 1568-1578
- https://doi.org/10.1038/sj.gt.3302309
Abstract
Three RNA features have been identified that elevate retroviral transgene expression: an intron in the 5' untranslated region (5'UTR), the absence of aberrant translational start codons and the presence of the post-transcriptional regulatory element (PRE) of the woodchuck hepatitis virus in the 3'UTR. To include such elements into self-inactivating (SIN) vectors with potentially improved safety, we excised the strong retroviral promoter from the U3 region of the 3' long terminal repeat (LTR) and inserted it either downstream or upstream of the retroviral RNA packaging signal (). The latter concept is new and allows the use of an intron in the 5'UTR, taking advantage of retroviral splice sites surrounding . Three LTR and four SIN vectors were compared to address the impact of RNA elements on titer, splice regulation and transgene expression. Although titers of SIN vectors were about 20-fold lower than those of their LTR counterparts, inclusion of the PRE allowed production of more than 106 infectious units per ml without further vector optimizations. In comparison with state-of-the-art LTR vectors, the intron-containing SIN vectors showed greatly improved splicing. With regard to transgene expression, the intron-containing SIN vectors largely matched or even exceeded the LTR counterparts in all cell types investigated (embryonic carcinoma cells, fibroblasts, primary T cells and hematopoietic progenitor cells).Keywords
This publication has 47 references indexed in Scilit:
- B-cell-specific transgene expression using a self-inactivating retroviral vector with human CD19 promoter and viral post-transcriptional regulatory elementGene Therapy, 2004
- RTCGD: retroviral tagged cancer gene databaseNucleic Acids Research, 2004
- LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1Science, 2003
- Occurrence of leukaemia following gene therapy of X-linked SCIDNature Reviews Cancer, 2003
- Progress and problems with the use of viral vectors for gene therapyNature Reviews Genetics, 2003
- High-level ectopic HOXB4 expression confers a profound in vivo competitive growth advantage on human cord blood CD34+ cells, but impairs lymphomyeloid differentiationBlood, 2003
- In Vivo Analysis of Retroviral Enhancer Mutations in Hematopoietic Cells: SP1/EGR1 and ETS/GATA Motifs Contribute to Long Terminal Repeat SpecificityJournal of Virology, 2002
- A New RNA Element Located in the Coding Region of a Murine Endogenous Retrovirus Can Functionally Replace the Rev/Rev-Responsive Element System in Human Immunodeficiency Virus Type 1 Gag ExpressionJournal of Virology, 2001
- Plat-E: an efficient and stable system for transient packaging of retrovirusesGene Therapy, 2000
- Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirementsGene Therapy, 1999